Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ: SILO )

1.840 +0.060 (+3.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,637
Open 1.810
Bid (Size) 1.830 (5)
Ask (Size) 1.880 (1)
Prev. Close 1.780
Today's Range 1.800 - 1.904
52wk Range 0.7700 - 4.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
From Silo Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+93.68%
+93.68%
1 Month
+106.74%
+106.74%
3 Month
+62.83%
+62.83%
6 Month
-10.68%
-10.68%
1 Year
+19.48%
+19.48%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Silo Pharma Shares Are Surging Today: What's Going On?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Crude Oil Down 1%; US Weekly Jobless Claims Decline
Via Benzinga
Exposures Fossil Fuels
US Stocks Down; Acuity Brands Posts Weak Revenue
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
Via Investor Brand Network
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partners with Kymanox to Advance Ketamine Implant Therapeutic for Chronic Pain
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Silo Pharma Stock Gaining Today?
Via Benzinga
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Promising Preclinical Results for SPC-15 in Treating Severe Psychiatric Disorders
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
Via Investor Brand Network
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
Via Investor Brand Network
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.